ClinicalTrials.gg
RecruitingNCT06617312CytisiniclineUpdated Dec 3, 2025

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

A Phase 2 interventional study of Cytisinicline and Placebo Oral Capsule in Smoking Cessation and Tobacco Use Disorder, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by University of California, Los Angeles · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Planned enrollment
14th of 22
64 · median 202
Started
2024
with 2 others
Phase 2
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
University of California, Los Angeles

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 2, and was the 21st registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.

Read the detailed description

The objective of this study is to examine the effects of cytisinicline on neural substrates of cigarette cue-reactivity. We will randomize 64 adults who smoke cigarettes daily (N=32 cytisinicline, N=32 placebo; 50% female) into a double-blind, placebo-controlled laboratory study of cytisinicline. Specifically, participants will complete a 2- to 3-week outpatient protocol that includes taking cytisinicline (3 mg, 3 times daily) or matched placebo (0 mg, 3 times daily) and completing a brief daily diary assessment of cigarette use and craving. Following 2- to 3-weeks of cytisinicline (or placebo) treatment, participants will complete a cigarette cue-exposure task during fMRI. Total study participation will be approximately 4 weeks.

03

Conditions studied

  • Smoking Cessation
  • Tobacco Use Disorder

Keywords

  • smoking cesstion
  • tobacco use disorder
  • cigarette smoking
  • fMRI
  • cytisinicline
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be between the ages of 18 and 65 and provide ;
  2. smoke 5 or more combustible cigarettes per day;
  3. not seeking treatment for smoking;

Exclusion criteria

Exclusion Criteria:

  1. current use of other smoking cessation aid (bupropion, varenicline, nortriptyline, NRT);
  2. more than 3 months of smoking abstinence in past year;
  3. use of non-cigarette tobacco product (pipe tobacco, cigars, smokeless tobacco, hookah) or electronic cigarettes more than 5 times in the 28-days prior to enrollment;
  4. current use of psychoactive drug (excluding cannabis), as determined by urine toxicology;
  5. current (past 12-month) diagnosis of substance use disorder for any substances other than tobacco and mild cannabis or mild-to-moderate alcohol use disorders;
  6. lifetime history of psychotic disorders, bipolar disorders, or major depression with suicidal ideation;
  7. current suicidal ideation or lifetime history of suicide attempt;
  8. serious medical illness within past 3 months, including recent history of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident, or hospitalization for congestive heart failure;
  9. medical condition that may interfere with safe study participation;
  10. renal impairment defined as a (CrCl) greater than 60 mL/min (estimated with the Cockroft-Gault equation);
  11. exceed Grade 2 laboratory abnormalities, based on FDA Guidance Document "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials";
  12. uncontrolled hypertension (blood pressure ≥160/100 mmHg);
  13. abnormal ;
  14. non-removable ferromagnetic object in body;
  15. claustrophobia;
  16. serious head injury or period of unconsciousness (more than 30 minutes);
  17. more than 250lbs;
  18. Be pregnant, nursing, or planning to become pregnant while taking part in the study; and must agree to one of the following methods of (if female), unless she or partner are surgically sterile:

    • Oral contraceptives
    • Contraceptive sponge
    • Patch
    • Double barrier
    • Intrauterine contraceptive device
    • Etonogestrel implant
    • Medroxyprogesterone acetate contraceptive injection
    • Hormonal vaginal contraceptive ring
    • Complete abstinence from sexual intercourse;
  19. have experienced adverse effects to varenicline;
  20. have an intense fear of needles or have had an adverse reaction to needle puncture.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cytisinicline

    3mg cytisinicline oral capsule 3 times daily for 2-to-3 weeks

    Drug: Cytisinicline

  • Placebo comparator
    Placebo

    matched to experimental drug

    Drug: Placebo Oral Capsule

Interventions

  • DrugCytisineStudies of CytisineCytisine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Targets α4β2 nicotinic acetylcholine receptors

  • DrugPlacebo Oral Capsule

    Matched to active drug, cytisinicline

06

What researchers measure

Primary outcomes

  1. Blood-oxygen-level-dependent (BOLD) activation to cigarette cues during fMRI task

    Participants will complete a cigarette cue-exposure task during fMRI. In this paradigm, participants are exposed to videotaped cues of smoking and control, non-cigarette related, content. Blood-oxygen-level-dependent (BOLD) activation to cigarette (vs. non-cigarette control ) cues will be calculated.

    Time frame: From enrollment to end of treatment at 2-to-3 weeks

Secondary outcomes

  1. In-scanner cigarette cue-induced subjective craving

    In-scanner cigarette cue-induced subjective craving ratings will be obtained following each cue exposure during the fMRI task.

    Time frame: From enrollment to end of treatment at 2-to-3 weeks

  2. Subjective cigarette craving during outpatient period

    Subjective cigarette craving, as assessed via daily diary self-report assessments, during the outpatient medication period

    Time frame: From enrollment to end of treatment at 2-to-3 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 42 non-industry phase 2 interventional studies under Smoking Cessation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 51 studies reached it within 35 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 27, 2024
StartActual
Dec 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06617312
Responsible party
Lara Ray, PhD (Professor, University of California, Los Angeles) — Principal investigator
First posted
Sep 27, 2024
Start date
Dec 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 3, 2025

Study contacts

Dylan E Kirsch, PhD
Contact
dylankirsch@psych.ucla.edu
(310) 206-6756

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion